Abstract
Anifrolumab (ANI) is a monoclonal antibody targeting the interferon alpha receptor 1 (IFNAR1), used in patients with systemic lupus erythematosus (SLE). It has demonstrated particular efficacy in the cutaneous and musculoskeletal domains of SLE,1,2 leading to its inclusion in the 2023 European Alliance of Associations for Rheumatology (EULAR) SLE treatment recommendations as an effective drug to control SLE flares and taper prednisone dose.3
